Biosimilar Introduction: CVS Health announced the inclusion of biosimilars Prolia and Forteo in its commercial formularies, replacing brand-name drugs from Amgen and Eli Lilly, expected to provide over 50% cost savings for patients.
Significant Cost Savings: The low-cost alternatives from CVS's biosimilar unit Cordavis and companies like Celltrion will help generate $1.5 billion in gross savings for customers and patients, significantly reducing the financial burden of osteoporosis treatments.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.